{"id":"https://openalex.org/W2243193473","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.4009","title":"Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial","display_name":"Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial","publication_year":2004,"publication_date":"2004-07-15","ids":{"openalex":"https://openalex.org/W2243193473","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.4009","mag":"2243193473"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2004.22.14_suppl.4009","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.4009","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.14_suppl.4009","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5090156519","display_name":"Hedy Lee Kindler","orcid":"https://orcid.org/0000-0002-5450-842X","observed_orcids":["https://orcid.org/0000-0002-5450-842X"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H. L. Kindler","raw_affiliation_strings":["University of Chicago, Chicago, IL; University of Chicago Phase II Consortium, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, IL; University of Chicago Phase II Consortium, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042578919","display_name":"Gregory R. Friberg","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"G. Friberg","raw_affiliation_strings":["University of Chicago, Chicago, IL; University of Chicago Phase II Consortium, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, IL; University of Chicago Phase II Consortium, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088131964","display_name":"Walter Michael Stadler","orcid":"https://orcid.org/0000-0002-0435-2527","observed_orcids":["https://orcid.org/0000-0002-0435-2527"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"W. M. Stadler","raw_affiliation_strings":["University of Chicago, Chicago, IL; University of Chicago Phase II Consortium, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, IL; University of Chicago Phase II Consortium, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103371208","display_name":"Deepti A. Singh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. A. Singh","raw_affiliation_strings":["University of Chicago, Chicago, IL; University of Chicago Phase II Consortium, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, IL; University of Chicago Phase II Consortium, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007560050","display_name":"Gershon Y. Locker","orcid":"https://orcid.org/0000-0002-6869-8738","observed_orcids":["https://orcid.org/0000-0002-6869-8738"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"G. Locker","raw_affiliation_strings":["University of Chicago, Chicago, IL; University of Chicago Phase II Consortium, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, IL; University of Chicago Phase II Consortium, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060130258","display_name":"Sreenivasa R. Nattam","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Nattam","raw_affiliation_strings":["University of Chicago, Chicago, IL; University of Chicago Phase II Consortium, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, IL; University of Chicago Phase II Consortium, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021535454","display_name":"Mark F. Kozloff","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Kozloff","raw_affiliation_strings":["University of Chicago, Chicago, IL; University of Chicago Phase II Consortium, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, IL; University of Chicago Phase II Consortium, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066578904","display_name":"Kristen Kasza","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K. Kasza","raw_affiliation_strings":["University of Chicago, Chicago, IL; University of Chicago Phase II Consortium, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, IL; University of Chicago Phase II Consortium, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5063904421","display_name":"Everett E. Vokes","orcid":"https://orcid.org/0000-0002-8645-8068","observed_orcids":["https://orcid.org/0000-0002-8645-8068"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E. E. Vokes","raw_affiliation_strings":["University of Chicago, Chicago, IL; University of Chicago Phase II Consortium, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, IL; University of Chicago Phase II Consortium, Chicago, IL","institution_ids":["https://openalex.org/I40347166"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I40347166"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":51,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"22","issue":"14_suppl","first_page":"4009","last_page":"4009"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10231","display_name":"Pancreatic and Hepatic Oncology Research","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10231","display_name":"Pancreatic and Hepatic Oncology Research","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.005799999926239252,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9940000176429749},{"id":"https://openalex.org/keywords/gemcitabine","display_name":"gemcitabine","score":1.0},{"id":"https://openalex.org/keywords/advanced-pancreatic-cancer","display_name":"advanced pancreatic cancer","score":0.9950000047683716},{"id":"https://openalex.org/keywords/anti-vegf-therapy","display_name":"anti-VEGF therapy","score":0.9670000076293945},{"id":"https://openalex.org/keywords/vascular-endothelial-growth-factor","display_name":"vascular endothelial growth factor","score":0.9200000166893005},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.8610000014305115},{"id":"https://openalex.org/keywords/partial-response","display_name":"partial response","score":0.6000000238418579},{"id":"https://openalex.org/keywords/stable-disease","display_name":"stable disease","score":0.75},{"id":"https://openalex.org/keywords/time-to-progression","display_name":"time to progression","score":0.8709999918937683},{"id":"https://openalex.org/keywords/survival","display_name":"survival","score":0.8889999985694885},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.8579999804496765},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.8109999895095825},{"id":"https://openalex.org/keywords/intestinal-perforation","display_name":"intestinal perforation","score":0.8159999847412109},{"id":"https://openalex.org/keywords/liver-metastases","display_name":"liver metastasis","score":0.7440000176429749},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.593999981880188}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.921877384185791},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.8022301197052002},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.7968094348907471},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5432875752449036},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.541258692741394},{"id":"https://openalex.org/C2777025900","wikidata":"https://www.wikidata.org/wiki/Q29725","display_name":"Vascular endothelial growth factor","level":3,"score":0.5258688926696777},{"id":"https://openalex.org/C2780210213","wikidata":"https://www.wikidata.org/wiki/Q212961","display_name":"Pancreatic cancer","level":3,"score":0.4978981018066406},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.45443645119667053},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.43772539496421814},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.419016569852829},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4165782928466797},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3524707853794098},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.34617018699645996},{"id":"https://openalex.org/C167734588","wikidata":"https://www.wikidata.org/wiki/Q4356503","display_name":"VEGF receptors","level":2,"score":0.16541936993598938}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2004.22.14_suppl.4009","doi":"https://doi.org/10.1200/jco.2004.22.14_suppl.4009","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.14_suppl.4009","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"doi:10.1200/jco.2004.22.90140.4009","doi":"https://doi.org/10.1200/jco.2004.22.90140.4009","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2004.22.90140.4009","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3010703934","https://openalex.org/W2124863710","https://openalex.org/W2590893558","https://openalex.org/W2084555154","https://openalex.org/W36351291","https://openalex.org/W1975193398","https://openalex.org/W2128095147","https://openalex.org/W2339361819","https://openalex.org/W2263750187","https://openalex.org/W4238710595"],"abstract_inverted_index":{"4009":[0],"Background:":[1],"Vascular":[2],"endothelial":[3],"growth":[4,21],"factor":[5],"(VEGF)":[6],"and":[7,22,35,263,306,317,339],"its":[8],"receptors":[9],"are":[10,64,132,140,182,196,322],"overexpressed":[11],"in":[12,38,50,72,187,280,308,334,336],"PC.":[13,51,310],"In":[14],"preclinical":[15],"models,":[16],"anti-VEGF":[17,45],"antibodies":[18],"suppress":[19],"PC":[20,39,74],"potentiate":[23],"the":[24,318,337],"activity":[25],"of":[26,70,97,171,206,218,314,329],"gemcitabine.":[27],"High":[28],"VEGF":[29,138,278],"expression":[30],"correlates":[31],"with":[32,289],"advanced":[33,73,309],"stage":[34,159],"decreased":[36],"survival":[37,233,242,297,313,321],"pts.":[40],"These":[41],"data":[42],"suggest":[43],"that":[44],"therapy":[46],"may":[47],"have":[48,81,173],"utility":[49],"Bevacizumab":[52],"(Avastin)":[53],"is":[54,107,123,225,234,243,304,333],"a":[55,66,88,204,216],"recombinant":[56],"humanized":[57],"monoclonal":[58],"antibody":[59],"to":[60,223],"VEGF.":[61],"Methods:":[62],"We":[63],"conducting":[65],"phase":[67,326],"II":[68],"trial":[69,190,328],"BG":[71,172,303,330],"pts":[75,80,144,181,210,282],"at":[76],"8":[77],"centers.":[78],"Eligible":[79],"no":[82,94,100,287],"prior":[83,165],"chemotherapy":[84],"(except":[85],"5-FU":[86],"as":[87],"radiosensitizer);":[89],"PS":[90],"0\u20132;":[91],"measurable":[92],"disease;":[93],"tumor":[95],"invasion":[96],"major":[98],"vessels;":[99],"bleeding":[101],"or":[102,296,351,354],"thrombosis.":[103],"G":[104,332],"1000":[105],"mg/m2":[106],"given":[108,124],"over":[109],"30":[110],"minutes":[111],"days":[112],"(D)":[113],"1,":[114,126],"8,":[115],"15":[116,127],"every":[117,128,134],"28":[118],"D.":[119],"B":[120],"10":[121],"mg/kg":[122],"D":[125],"28D.":[129],"CT":[130],"scans":[131],"obtained":[133,141],"2":[135],"cycles.":[136],"Plasma":[137],"levels":[139,279],"pretreatment.":[142],"45":[143],"enrolled":[145],"11/01\u201312/03.":[146],"Pt":[147],"characteristics:":[148],"male":[149],"47%;":[150],"median":[151,205,217,312],"age":[152],"61":[153],"(range":[154,283],"42\u201383);":[155],"PS:":[156],"0/1/2:":[157],"62%/36%/2%;":[158],"IV":[160],"100%;":[161],"liver":[162],"metastases":[163],"80%;":[164],"radiation":[166],"18%.":[167],"Results:":[168],"182":[169],"cycles":[170],"been":[174],"administered":[175],"(median":[176,191],"3,":[177],"range":[178],"<1\u201311).":[179],"42":[180],"currently":[183],"evaluable":[184],"for":[185],"response":[186,291],"this":[188],"ongoing":[189],"follow-up":[192],"5.7":[193],"months).":[194],"There":[195],"9":[197],"confirmed":[198],"partial":[199],"responses":[200],"(21%":[201],"PR)":[202],"lasting":[203,215],"9.4":[207],"months.":[208,220],"19":[209],"(45%)":[211],"had":[212],"stable":[213],"disease":[214],"5.4":[219],"Median":[221,232],"time":[222],"progression":[224],"5.8":[226],"months":[227,236,316],"(95%":[228,237],"CI:":[229,238],"4.8,":[230],"9.1).":[231],"9.0":[235,315],"7.4,":[239],"12.4);":[240],"6-month":[241,320],"74%.":[244],"Grade":[245,267],"\u00be":[246],"toxicities":[247],"(%":[248],"pts):":[249],"neutropenia":[250],"33%;":[251],"leukopenia":[252],"30%;":[253],"thrombocytopenia":[254],"7%;":[255],"thrombosis":[256],"12%;":[257],"bowel":[258,274],"perforation":[259],"5%;":[260],"hypertension,":[261],"proteinuria,":[262],"headache":[264],"2%":[265],"each.":[266],"5":[268],"toxicities:":[269],"1":[270,273],"gastrointestinal":[271],"bleed,":[272],"perforation.":[275],"Pretreatment":[276],"plasma":[277],"32":[281],"0\u2013586":[284],"pg/ml)":[285],"showed":[286],"correlation":[288],"either":[290],"(Fisher's":[292],"exact":[293],"test":[294,300],"p=1.00)":[295],"(Log":[298],"rank":[299],"p=0.70).":[301],"Conclusion:":[302],"active":[305],"well-tolerated":[307],"The":[311],"74%":[319],"encouraging.":[323],"A":[324],"randomized":[325],"III":[327],"vs.":[331],"development":[335],"Cancer":[338],"Leukemia":[340],"Group":[341],"B.":[342],"Supported":[343],"by":[344],"NCI":[345],"grant":[346],"N01-CM-17102.":[347],"Author":[348],"Disclosure":[349],"Employment":[350],"Leadership":[352],"Consultant":[353],"Advisory":[355],"Stock":[356],"Ownership":[357],"Honoraria":[358],"Research":[359],"Funding":[360],"Expert":[361],"Testimony":[362],"Other":[363],"Remuneration":[364],"Genentech;":[365],"Lilly":[366,369,371],"Oncology":[367,370,372],"Genentech":[368]},"counts_by_year":[{"year":2018,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2016-06-24T00:00:00"}